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Summary 
Asthma is a disease of airway inflammation and hyperreactivity that is associated with a lymphocytic 
infiltrate in the bronchial submucosa. The interactions between infiltrating T lymphocytes with 
cellular and extraceUular matrix components of the airway and the consequences of these interactions 
have not been defined. We demonstrate the constitutive expression of CD44 on human airway 
smooth muscle (ASM) cells in culture as well as in human bronchial tissue transplanted into 
severe combined immunodeficient mice. In contrast, basal levels of intercellular adhesion molecule 
1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) expression are minimal but are 
induced on ASM by inflammatory mediators such as tumor necrosis factor ot (TNF-ct). Activated, 
but not resting T cells, adhere to cultured ASM; stimulation of the ASM with TNF-a enhanced 
this  adhesion.  Adhesion was partially blocked by monoclonal antibodies  (mAb)  specific for 
lymphocyte function-associated antigen 1 (LFA-1) and very late antigen 4 (VLA-4) on T  cells 
and ICAM-1 and VCAM-1 on ASM cells. The observed integrin-independent adhesion was mediated 
by CD44/hyaluronate interactions as it was inhibited by anti-CD44 mAb 5F12 and by hyaluronidase. 
Furthermore, the adhesion of activated T lymphocytes induced DNA synthesis in growth-arrested 
ASM cells. Thus, the interaction between T cells and ASM may provide insight into the mechanisms 
that induce bronchial inflammation and possibly ASM cell hyperplasia seen in asthma. 
A 
thma,  a disease of reversible  bronchial obstruction,  is 
characterized by airway inflammation, epithelial damage, 
airway smooth muscle hyperplasia, and airway hyperrespon- 
siveness. Although the eosinophil is one important effector 
cell in asthma, other inflammatory cells,  particularly lym- 
phocytes, are postulated to be critical in the initiation and 
perpetuation of airway inflammation. Bronchial biopsies from 
asthmatics exhibit increased numbers of lymphocytes in the 
submucosa (1).  In addition,  an increase in the number of 
CD4 + T cells with a phenotype associated with T cell acti- 
vation is found in bronchoalveolar lavage of asthma patients 
(2-4). Activated T lymphocytes secrete a pattern of cytokines, 
including IL-4 and IL-5, characteristic of a Th2 phenotype 
(4). In turn, these cytokines promote allergic type inflamma- 
tory responses such as eosinophil recruitment and isotype 
switching of B cells to production of IgE (5). 
In addition to secreting cytokines, T lymphocytes interact 
with other cell types by direct cell-cell contact. Recent at- 
tention has been directed toward the role of cell adhesion mol- 
ecules in mediating airway inflammation (6). Previous studies 
showed increased expression of the/$1 and/32 integrins very 
late antigen 4 (VLA-4) 1 and LFA-1,  as well as of CD44,  a 
receptor for hyaluronate (HA), on leukocytes recovered from 
the airways of patients  with  asthma (7,  8).  Furthermore, 
Wegner et al. (9) demonstrated that antibodies against inter- 
cellular adhesion molecule 1 (ICAM-1), a counter-receptor 
for LFA-1,  decreased eosinophil infiltration, and attenuated 
bronchial hyperresponsiveness in a primate model of asthma. 
Adhesion molecules also mediate lymphocyte-endothelial cell 
interactions during the process of cell recruitment and homing. 
Although extravasation of lymphocytes from the circulation 
is a relatively well defined early step in establishing a local 
inflammatory response, the subsequent interactions of the 
infiltrating lymphocytes with other cell types in the bron- 
chial submucosa or extracellular matrix, a step that may be 
1 Abbreviations used in this paper: ASM, airway smooth muscle; BrdU, 
bromodeoxyuridine; HA, hyaluronate; ICAM-1, intercellular  adhesion 
molecule  1;  PDBU, phorbol 12,13-dibutyrate; PECAM-1, platelet 
endothelial cell adhesion molecule 1; VCAM-1, vascular cell adhesion 
molecule 1; VLA-4, very  late antigen 4; VSM, vascular smooth muscle. 
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largely unstudied. 
Infiltrating lymphocytes are in close proximity with airway 
smooth muscle (ASM) cells, a cell type that is important in 
the pathogenesis of asthma.  Interestingly, virtually nothing 
is known about the expression or function of adhesion mole- 
cules on ASM cells. We postulated that ASM, like vascular 
smooth muscle (VSM), expresses cell adhesion molecules that 
may be upregulated during inflammation and that lympho- 
cyte-ASM interactions could have important  consequences 
for both cell types.  We therefore investigated the adhesion 
molecule repertoire of ASM,  the potential for and mecha- 
nisms of lymphocyte-ASM interactions to occur, and the con- 
sequences of such cell-cell interactions. 
Materials and Methods 
mAbs.  The following routine mAbs specific for human antigens 
were  used:  RR6.5  (anti-ICAM-1,  gift  of  Dr.  R.  Rothlein 
[Boehringer Ingdheim Pharmaceuticals, Inc., Ridgefield, CT] [10]), 
4B9 (anti-vascular  cell adhesion molecule 1 [VCAM-1] gift of Dr. 
T. Carlos [University of Pittsburgh, Pittsburgh,  PAl  [11]), 5F12 
(blocking anti-CD44, gift of Dr. B. Haynes [Duke University Med- 
ical Center, Durham,  NC] [12]), Hermes III [nonblocking anti- 
CD44 [Stanford University, Palo Alto, CA] [13]), 4G6 (anti-platelet 
endothelial cell adhesion molecule 1 [PECAM-1] [14]), TS1/22 (anti- 
LFA-1 c~ chain [American Type Culture Collection, Rockville, MD] 
[15]),  163H (anti-VLA-4,  gift of Dr. W.  Gallatin [ICOS Corp., 
Bothell,  WA  D,  DREG  56  (anti-t-selectin,  gift  of Dr.  T.  K. 
Kishimoto  [Boehringer Ingelheim  Pharmaceuticals,  Inc.]  [16]). 
RR6.5, 4B9, Hermes III, 4G6, and DREG 56 were used at a con- 
centration of 10/~g/ml of purified antibody. TS1/22 was purified 
from an ammonium sulfate cut of serum-free superuatant and 5F12 
was provided as a hybridoma superuatant. KM201 (rat antimurine 
CD44 [Dr. P. Kincade,  Oklahoma Medical Research Foundation, 
Oklahoma City, OK] [17]) was purified from an ammonium sul- 
fate cut of serum-free supernatant. 
T Cells.  Peripheral blood was obtained by venipuncture from 
healthy volunteers and the T cells purified (>95% CD3 § by flow 
cytometry) by Ficoll (Pharmacia LKB, Piscataway, NJ) density gra- 
dient  centrifugation  and  rosetting  with  neuraminidase-treated 
(Sigma Chemical Co., St. Louis, MO) sheep erythrocytes (Rock- 
land Inc., Gilbertsville, PA) (18). Cells were maintained in RPMI 
1640 supplemented with 10% FCS, 2 mM glutamine, 100/zg/ml 
gentamicin, 100 U/ml penicillin, 100 #g/ml streptomycin, and 2.5 
/xg/ml fungizone. Where indicated, T  cells were activated with 
phorbol 12,13-dibutyrate (PDBU, 5 ng/ml; Sigma Chemical Co.) 
and ionomycin (250 nM; Sigma Chemical Co.) for 42 h at 37~ 
T cells used for adhesion assays were pulsed with [3H]thymidine 
(1 #Ci/106 cells; New England Nuclear, Boston, MA) for the final 
16 h of incubation. 
.ASM.  Human ASM cells were isolated from the trachealis 
muscle of lung transplant  donors and purified as described by Panet- 
tieri et al. (19). These cells retain smooth muscle-specific actin ex- 
pression as well as responsiveness to contractile agonists (19). Cells 
were maintained in Ham's F12 media supplemented with 10% FCS, 
2 mM glutamine, 25 mM Hepes, 12 mM NaOH, 1.5 mM CaClz, 
100 U/ml penicillin, and 100/~g/ml streptomycin. For the DNA 
synthesis experiments, cells were quiesced in serum-free Ham's F12 
media supplemented with 5.7/xg/ml insulin, 5/zg/ml transferrin, 
2 mM glutamine, 1.5 mM CaC12, 25 mM Hepes, 100 U/ml pen- 
icillin,  and 100/zg/ml streptomycin. 
Flow Cytometry.  ASM cells were recovered by digestion with 
trypsin/EDTA  and  reacted  with  mAb  specific for PECAM-1, 
ICAM-1, or VCAM-1 for 45 min at 4~  followed by FITC goat 
anti-mouse IgG (Organon Teknika Corp., Durham, NC). Samples 
were analyzed using an Ortho Cytofluorograf  System 50, connected 
to a 2150 Data Handling System (Ortho Diagnostic Systems, Inc., 
Raritan,  NJ). 
Immunoprecipitation.  Confluent ASM cells grown in a T25 flask 
were depleted in methionine-free media for 1 h and incubated over- 
night  with  [35S]methionine  (200  /zCi;  Amersham  Corp., 
Arlington Heights, IL). After labeling, cells were washed and lysed 
in 10 mM Tris, 0.5% NP-40, 0.5 mM CaC12 and 1 mM phenyl 
methyl sulfonyl fluoride.  Lysates were fractionated by centrifuga- 
tion at  10,000 g  and the NP-40--soluble  extract precleared  with 
Sepharose-protein A, 150 mM NaC1, 4% BSA. Lysates were reacted 
with murine mAb specific for ICAM-1, VCAM-1, CD44 (Hermes 
III), or PECAM-1,  and the immune complex precipitated with 
Sepharose-protein A. Precipitates  were washed with 0.5% deoxy- 
cholic acid, 50 mM Tris, 150 mM NaC1,  1% Triton X-100, 0.1% 
SDS. The immune complexes were then eluted by boiling in 2 x 
Laemmli buffer and resolved by electrophoresis on a 6% nonreduced 
polyacrylamide gel. 
Quantitative Adhesion Assay.  Confluent ASM monolayers were 
treated  with  control  media  or  1000  U/ml  TNF-ce  for 24  h. 
[3H]thymidine-labeled  activated  T  cells  were  washed  and 
pretreated with murine mAbs specific for anti-LFA-1, anti-VLA-4, 
anti-CD44 (5F12), or normal mouse IgG (Fisher Scientific, Pitts- 
burgh,  PA) for 45 min at 4~  Where stated,  ASM cells were 
pretreated with mAbs specific for anti-ICAM-1 or anti-VCAM-1 
for 45 min at 4~  Cells  (6  x  10S/well) were added  to resting 
or TNF-o~-stimulated ASM monolayers in 24-well tissue culture 
plates  and allowed  to adhere for 1 h at 37~  Nonadherent cells 
were removed by washing. Adherent cells were lysed with 1% Triton 
X-100 and quantitated by scintillation spectroscopy. Percent binding 
were calculated as counts recovered from adherent cells/total input 
counts  x 100. Each condition was performed in triplicate and data 
were  expressed  as  mean  percent  binding  _+  SD.  Statistical 
significance was analyzed with a one way analysis of variance using 
the Bonferonni-Dunn test. 
Detection  of  DNA  Synthesis.  ASM  cells  were  grown  to 
subconfluence in 2-well slide culture fasks and serum-deprived for 
48 h to establish quiescence.  Resting or activated T cells were ir- 
radiated  with  3,500  rad  using  a  137Cs source.  T  cells  (5  x 
105/well) were then added to the ASM and allowed to adhere for 
42 h. During the final 24 h, cultures were incubated with 20 #M 
bromodeoxyuridine (BrdU; Sigma Chemical Co.). The slides were 
washed once with PBS, fixed in 70% ethanol for 30 min at room 
temperature, and allowed  to air dry. Slides were exposed to 1 N 
HC1 for 5 min and washed with PBS. Primary antibody staining 
was performed with the hybridoma culture supernatant containing 
anti-BrdU mAb BU-1 (20) and detected with 10/~g/ml of FITC- 
sheep anti-mouse IgG (Boehringer Mannheim, Indianapolis,  IN). 
The cells were then counterstained with Evan's blue. Nuclei were 
visualized using a Leitz fluorescent microscope equipped with stan- 
dard fluorescein and rhodamine filters. Random high power fields 
were chosen and photographed or the nuclei counted. The mitotic 
index was calculated as the ratio of BrdU positive nuclei/total nuclei 
_+ SEM from 50 high power fields for each condition from three 
separate experiments. Statistical significance was determined using 
one way analysis of variance. 
CD44  Transfectants.  The  stable  AKR1.G10  transfectant  ex- 
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from Dr. J. Lesley  and Dr. R. Hyman (The Salk Institute, La Jolla, 
CA)  (21). 
SCID Model.  Human bronchial xenografts were established as 
previously  described (22). Briefly,  segments of second to fifth gener- 
ation human airway were dissected from surrounding  adventitial 
tissue and transplanted subcutaneously into both flanks of SCID 
mice (23) obtained  from a colony maintained  in pathogen-free 
housing at the Wistar Institute.  In this model, xenografts become 
revascularized within I wk of transplant and have a normal histo- 
logic appearance with little evidence  of tissue rejection. A xenograft 
in one flank was injected with 50/~1 of endotoxin-free saline con- 
taining 2 mg/ml BSA (Sigma Chemical Co.) as a protein carrier 
plus 1% colloidal  carbon to identify the injection site. The xenograft 
on the contralateral side was injected with 6,000 U of recombinant 
human TNF-ce (provided by Genentech Inc., S. San Francisco, CA) 
diluted in 50 #1 endotoxin-ffee saline containing  2 mg/ml BSA. 
6 or 18 h after the injection the xenografts were removed and flash 
frozen at  -70~  Frozen sections were stained as previously de- 
scribed (22). Primary antibody was detected using the Vectastain 
ABC Elite Kit (Vector Laboratories, Inc.,  Burlingame,  CA). 
Results 
Constitutive and TNF-c~-inducible Expression of  Adhesion Mol- 
ecules on ASM Cells In  Vitro.  Analysis of immunoprecipi- 
tates  of  extracts  of  [3SS]methionine-labeled  ASM  cells 
demonstrated constitutive expression of the "~90-kD hema- 
topoietic form of CD44  that was not changed by treating 
the ASM with TNF-o~ (Fig.  1).  In contrast, ICAM-1 was 
expressed at low levels and VCAM-1 was not detectable on 
untreated ASM cells; both were markedly upregulated after 
treatment with TNF-a for 24 h. Binding ofradiolabeled anti- 
ICAM-1 antibody (data not shown) and immunofluorescent 
flow cytometry of single cell suspensions of ASM cells (Fig. 
2) confirmed the cy.tokine-inducible expression of ICAM-1 
and VCAM-1 on the cell surface.  There was no expression 
of E-selectin on either resting or TNF-c~-stimulated ASM 
(data not shown). 
TNF-o~ induction of ICAM-1 expression on ASM was dose 
and time dependent. Confluent ASM cells were stimulated 
with varying concentrations of TNF-oe for 24 h and analyzed 
by flow cytometry. TNF-oMnduced expression of ICAM-1 
was detectable with  10 U/ml TNF and linear up to 1,000 
U/ml TNF (Fig. 3 A). To determine the kinetics of ICAM-1 
expression, confluent ASM cells were stimulated with  100 
U/ml of TNF-oe and changes in surface expression of ICAM-1 
were determined between 0  and 48 h  by flow cytometry. 
ICAM-1 expression was detectable by 4 h  and maximal at 
36 h  (Fig.  3 B). 
Flow cytometry was  also  used to compare the effect of 
several other inflammatory mediators on ICAM-1 and VCAM-1 
expression on ASM in vitro. Treatment with IL-1, LPS, and 
IFN-y  for  24  h  increased  ICAM-1  expression,  whereas 
VCAM-1  expression was  most  notably increased by IL-1 
(Fig.  2). 
Adhesion Molecule Expression on ASM In Viva  We extended 
the in vitro findings using an in vivo model of human bron- 
chial tissue transplanted onto the flank of SCID mice (22). 
Figure  1.  Constitutive  and TNF-c~-inducible  expression  of cell adhe- 
sion molecules  on ASM. Immunoprecipitation  of  lysates from  resting and 
TNF-o~-stimulated ASM. [3SS]methionine-labeled  protein from resting 
and TNF-ol-stimulated  (100 U/ml) ASM was precipitated  with mAbs as 
indicated and resolved on a 6% SDS-PAGE gel. 
Immunocytochemistry of frozen sections of the bronchial 
xenograft (Fig.  4) demonstrated that  minimal amounts of 
ICAM-1 and VCAM-1 were expressed on the ASM cells as 
identified by staining for smooth muscle actin (Fig. 4, C and 
F) in untreated grafts (Fig. 4, A  and B). However, injection 
of TNF-a into the bronchial lumen of the graft induced a 
ICAM-1  VCAM-1 
~Untreated 
[ j~  .LPS 
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Fluorescence  intensity 
Figure 2.  Induction  of ICAM-1 and VCAM-1 by cytokines  and LPS. 
Confluent ASM was treated  with 100 U/ml TNF-ce, 10 U/ml IL-1, 100 
U/ml IFN-% or 1 #g/ml LPS for 24 h. Shaded areas represent profiles 
of a negative control antibody (anti-PECAM-1). Open curves represent 
staining with anti-ICAM-1 (left) or anti-VCAM-1 (right) mAbs. 
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Figure  3.  TNF-~-induced ICAM-I expression is dose and time dependent. (A) Dose-dependent induction of ICAM-1 expression by TNF-c~. Confluent 
ASM was stimulated with the indicated doses of TNF-ot for 24 h. (B) Kinetics of TNF-ot-induced ICAM-1 expression. Confluent ASM was stimulated 
with 100 U/ml TNF-ot for the times indicated.  Data are expressed as the ratio of mean fluorescent intensity of ICAM-1 mAb to an isotype matched 
negative control mAb  _+  SD. Data are representative  of four separate experiments. 
Figure 4.  Adhesion molecule expression on human 
bronchial  xenografts  in SCID mice. Frozen sections 
of human bronchial xenografts were analyzed by im- 
munohistochemical  staining for expression of (A, D, 
and G) ICAM-1; (B, E, and/-/) VCAM-1; (C and F) 
myocyte actin; and (/) CD44. The bronchial xenografts 
were  from  SCID  mice  treated  with  vehicle alone 
(A-C), 6 (D-F) or 18 h (G-/) after TYF-ot injection 
(6,000 U) directly into the graft.  Human bronchial 
tissue was grafted  onto the flank of a SCID mouse 
as previously  described  (22). Arrows  indicate  ASM 
tissue. marked upregulation of ICAM-1 after 6 h  (Fig.  4 D) and 
ICAM-1 and VCAM-1 after 18 h (Fig. 4, G and H) on the 
submucosal smooth muscle tissue.  In addition, there was 
marked expression of CD44 on both the ASM and the epi- 
thelium in both the TNF-c~-treated (Fig. 4/) and untreated 
(data not shown) xenografts. In addition, the expected in- 
creases in endothelial expression of ICAM-1 and VCAM-1 
in response  to TNF-ot stimulation were seen (Fig. 4, D, G, 
and H). 
Activated T Lymphocytes Adhere to ASM.  To examine the 
capacity of T cells to adhere to ASM, we performed a quan- 
titative adhesion assay. Between 5 and 10% of unstimulated 
T cells bound to resting ASM cells (Fig.  5). In contrast, up 
to 30% of activated T  cells bound to untreated ASM cells. 
Treatment of the ASM cells with TNF-ot for 24 h did not 
significantly increase adhesion of resting T cells, but enhanced 
adhesion of activated T cells up to 50%. This indicates that 
activation of T  lymphocytes is required for their adhesion 
to ASM cells. Although upregulated expression of cell adhe- 
sion receptors by the ASM cells was not sufficient to mediate 
resting T lymphocyte adhesion, it enhanced adhesion of ac- 
tivated T  cells. 
T Cell Adhesion to ASM Is Mediated by Lymphocyte Integrins 
and CD44.  The role of specific adhesion receptors in medi- 
ating  lymphocyte-ASM  binding  was  determined  using 
blocking mAbs (Fig.  6).  We observed partial inhibition of 
binding to TNF-ot-stimulated ASM when activated T cells 
were pretreated with mAbs against LFA-1 (Fig.  6, A  and 
B) or when the TNF-ot-stimulated ASM cells were pretreated 
with an antibody to ICAM-1 (Fig. 6 A). When used alone, 
antibodies specific for VLA-4 (Fig.  6, A  and B) or one of 
its ligands, VCAM-1 (Fig.  6 A), had little inhibitory effect 
on adhesion of activated T  cells to stimulated ASM. How- 
ever,  mAbs  against LFA-1  and VLA-4 used together,  or 
ICAM-1 and VCAM-1 in combination, inhibited binding 
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Figure  5.  Activated  T lymphocytes  adhere to ASM cells. T cells were 
cultured without (unstim) or with PDBU and ionomycin  (PDBU/Iono) 
and pulsed with [3H]thymidine  (1/~Ci/106 cells) for the final 16 h of a 
42-h culture period. ASM was stimulated  with control media or TNF-ot 
(1,000 U/ml) for 24 h. Percent adhesion  was quantitated  as described in 
Materials and Methods. Each condition  was performed  in triplicate and 
data are representative of five separate experiments. 
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Figure  6.  T cell adhesion to ASM is mediated  by LFA-1, VLA-4, and 
CD44. Activated  T cells  were pretreated  with mAbs specific  as indicated. 
ASM was stimulated  with TNF-cz (1,000 U/ml) for 24 h; cells were also 
pretreated with mAbs specific  for ICAM-1 and VCAM-1 where indicated. 
Percent adhesion  was quantitated  as described in Materials and Methods. 
Data from two (total n = 5) different  experiments (A and B) are shown. 
to a greater extent than anti-LFA-1 or anti-ICAM-1 alone. 
Adhesion of activated T cells to resting ASM, although less 
than adhesion to TNF-c~-treated ASM, was inhibited propor- 
tionally to  the  same  extent by these antibodies (data not 
shown). 
Since we observed significant adhesion even in the pres- 
ence of these combinations of  mAbs, we investigated the poten- 
tial role for a third adhesion pathway mediated by CD44- 
HA interactions. Pretreatment of T cells with a mAb specific 
for the HA binding site of CD44 (5F12) did not cause a de- 
crease in activated T lymphocyte adhesion to TNF-ot-stimu- 
lated ASM (Fig. 6 B). Pretreatment of the ASM monolayer 
with hyaluronidase also failed to decrease adhesion of acti- 
vated T  cells (data not shown). However, the combination 
of mAbs against LFA-1, VLA-4, and CD44 acted synergisti- 
cally, reducing the binding of activated T  cells to the level 
observed for resting T cells (Fig. 6 B). LFA-1/VLA-4-inde- 
pendent adhesion was also sensitive  to hyaluronidase treat- 
ment (data not shown). These data indicate that CD44 also 
plays a role in mediating T  cell adhesion to ASM and ac- 
counts for the integrin-independent adhesion. Pretreatment 
of activated T cells with mAbs against L-selectin or against 
an epitope of CD44 not involved in HA binding (Hermes 
III) had no effect on adhesion (data not shown). 
CD44 Is Sufficient to Mediate T Cell Adhesion to ASM.  We 
811  Lazaar  et al. observed that mAb against CD44 decreased T cell adhesion 
only in the absence ofintegrin-mediated adhesion. We there- 
fore determined whether CD44 was sufficient to mediate adhe- 
sion or whether it was dependent on LFA-1 and/or VLA-4. 
For this purpose, we exploited the fact that murine LFA-1 
does  not  bind  to  human  ICAM-1  (24),  whereas  CD44- 
mediated binding is not species  specific  (25). AKR1.G10 is 
a murine lymphoma line that expresses LFA-1, but not VLA-4 
or CD44. This line does not bind appreciably to HA unless 
transfected with CD44 (21). As expected, we also found that 
the LFA-1 expressed by this murine line could not mediate 
binding to human ASM cells. Thus, by comparing adhesion 
of the CD44-  AKR1.G10 cells and AKR1.G10 transfected 
with murine CD44, we could test for integrin-independent, 
CD44-mediated adhesion. Staining with fluorescein-labeled 
Hermes III or HA indicated  that  the AKR1.G10 transfec- 
tants expressed similar levels of active CD44 compared with 
activated T  lymphocytes (data not shown). AKR1.G10 cells 
transfected with vector alone did not bind significantly to 
human ASM, whereas cells transfected with murine CD44 
demonstrated •50%  binding (Fig.  7). This interaction was 
specific, as it was inhibited by the mAb KM201 that blocks 
the HA binding site of murine CD44 (Fig.  7) as well as by 
soluble HA (data not  shown).  Furthermore,  adhesion was 
reversible by digestion  with  hyaluronidase  (Fig.  7).  These 
studies indicate that CD44 is sufficient to mediate T cell adhe- 
sion to ASM under certain  conditions. 
T  Cell Adhesion Induces ASM DNA Synthesis.  Smooth 
muscle  cell  hypertrophy  and  hyperplasia  are  hallmarks  of 
asthma (26), however, the mechanisms that  induce this re- 
sponse in ASM cells remain unknown. We studied the effect 
of T  lymphocyte adherence on DNA synthesis in ASM as 
measured by uptake of BrdU (27).  We chose to use BrdU 
incorporation as a measure of DNA synthesis since this tech- 
nique can distinguish DNA synthesis in individual cells. This 
method also allowed us to characterize  the relationship be- 
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Figure 7.  CD44 is sufficient for T cell adhesion to ASM. AKKI.G10 
cells stably transfected with vector alone (hatched bars) or murine CD44 
(solid bars) were pulsed  with [3H]thymidine  for  16  h.  ASM cells were 
stimulated  with TNF-o~ (1,000 U/ml) for 24 h.  AKR1.G10  cells were 
pretreated  with control antibody or KM201  (50 #g/ml)  as indicated. 
Hyaluronidase  (200 #g/ml) was added  5 rain before completion of the 
adhesion assay. Each condition was performed in triplicate; data are repre- 
sentative  of two separate experiments. 
tween adherent  T  cells  to ASM cells that  had entered the 
cell cycle. Using fluorescence microscopy, we observed that 
irradiated activated T cells adhered and induced a significant 
increase in the number  of ASM cells  incorporating  BrdU, 
compared with no effect in ASM cells cocultured with resting 
T cells (Fig.  8, A and B vs. C and D). Immunohistochemical 
analysis with an antibody against BrdU revealed fluorescence 
in less than 0.3  _+  0.2%  of ASM maintained in serum-free 
media compared with 30 +  2.4% of ASM treated with 10% 
FCS, a potent ASM mitogen (27) (Fig. 9). BrdU incorpora- 
tion was detected in 8.8  _+  1.1% of growth-arrested ASM 
cocuhured with  activated T  lymphocytes, whereas neither 
unstimulated  T  cells nor the conditioned media from acti- 
vated T  cells  (data not shown) induced DNA synthesis.  In 
addition,  the supernatant  from ASM-T cell cocultures did 
not induce DNA synthesis in ASM (data not shown). Similar 
results  were obtained  when  uptake  of [3H]thymidine  was 
measured  (data not  shown). 
Discussion 
Adhesion of lymphocytes to endothelium is necessary for 
their migration  to areas of tissue injury. What are less well 
understood are the effector functions of these cells and the 
signals that contribute to ongoing immune stimulation once 
cells are recruited from the circulation. As lymphocytes mi- 
grate from the vascular space to the airway,  it is likely that 
they interact with both extracellular matrix components and 
with  the cellular components of the airway such as fibro- 
blasts, dendritic cells and smooth muscle cells (28). We show 
that ASM, both in vitro and in vivo, constitutively expresses 
high levels of CD44, and can be stimulated to express ICAM-1 
and VCAM-1 in response to inflammatory mediators  such 
as TNF-o~.  It is noteworthy,  therefore,  that  TNF-o~ levels 
are significantly increased in the bronchoalveolar lavage fluid 
from asthmatics compared with normal patients, with levels 
ranging  from 600 to  10,000 pg/ml  (29, 30).  Lymphocytes 
can interact with ASM cells in a regulated manner via specific 
adhesion receptors. Furthermore, the data illustrate that such 
interactions  can stimulate DNA synthesis in ASM, which 
may be relevant to mechanisms that induce ASM cell hyper- 
plasia. 
The few studies that have examined the expression or func- 
tion of adhesion molecules on smooth muscle cells have fo- 
cused on vascular tissue. Li et al.  (31) described an increase 
in VSM expression of VCAM-1 in response to IFN-3, and 
LPS, but not to IL-1 or TNF-o~. Couffinhal et al. (32) found 
that VSM treated with TNF-cr expressed functionally active 
ICAM-1  that  mediated  monocyte  binding.  In  addition, 
Stemme et al.  (33) demonstrated  that  ICAM-1  expression 
on VSM could be upregulated by IL-1, IFN-y, and LPS and 
was  accompanied by a  modest  increase  in  T  lymphoblast 
binding. In turn, binding could be partially inhibited by mAbs 
specific for ICAM-1,  LFA-1, and CD29,  implicating  these 
receptors in the adhesion of T  cells to VSM. However, the 
fact that blocking by these mAbs was incomplete suggests 
that  additional  adhesion pathways might  be involved with 
adhesion  to VSM as well. 
812  T  Lymphocytes  Adhere  to Airway Smooth Muscle Cells Figure 8.  Activated  T cells induce 
DNA synthesis in ASM. Representa- 
tive (n  =  4) fluorescent  photomicro- 
graph comparing  BrdU incorporation 
by ASM cells  cultured  with resting (A 
and B) or stimulated (C and D) T cells. 
Arrows indicate  T cells; ASM cell nuclei 
that stain  positive  for BrdU are yellow. 
Original magnification 800 x. 
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tion by ASM from a representative experiment (n  =  4) expressed as the 
ratio of positively  staining  nuclei/total nuclei  _+  SEM was determined 
under the indicated  conditions.  *p <.001  compared  with control. 
We observed that  adhesion of activated T  lymphocytes 
to ASM  was  also  only partially  mediated  by  an  LFA-1/ 
ICAM-1 interaction, and a role for VLA-4/VCAM-1 was 
only apparent in the absence of LFA-l-mediated adhesion. 
Similar findings  suggesting  the  preferential use of LFA-1 
over VLA-4 have also been reported for adhesion of activated 
T  cells  to endothelium (34-36).  We obtained no evidence 
to implicate L-selectin in adhesion of T  cells to ASM. This 
is in contrast to recent work suggesting that L-selectin is 
important in T  cell adhesion to resting and activated endo- 
thelium (34). 
One of the most important findings of this study was the 
definition of the integrin-independent adhesion of T cells to 
ASM as mediated by CD44. CD44, a glycoprotein with ho- 
mology to core and link proteins, has been shown to serve 
as a homing molecule and as a receptor for HA (25, 37-39). 
CD44 is expressed on a wide variety of cells and is present 
in an inactive form on resting lymphocytes. The physiologic 
stimuli that induce adhesion function of CD44 remain un- 
known. Engagement of other adhesion receptors may acti- 
vate CD44, either by increasing expression and/or by increasing its affinity for HA. Studies by Lesley et al.  (21, 40) indicate 
that cross-linking of CD44 by antibody can increase the affinity 
of CD44 for HA. In addition,  there is evidence that T  cell 
adhesion  to endothelium  is accompanied by the clustering 
of CD44 molecules on the surface of the lymphocyte oriented 
toward the endothelium  (41).  This receptor clustering may 
lead to intracellular  signaling,  effecting a further increase in 
adhesiveness of the integrin receptors such as LFA-1 (42-44). 
Similar examples of cross talk between receptors leading to 
cellular activation and adhesion have become increasingly rec- 
ognized  (45). 
The expression of CD44 on ASM cells  as well as on T 
lymphocytes, combined with the ability of hyaluronidase to 
disrupt the T cell-ASM interaction, suggests that T cell CD44 
binds to ASM-associated HA and that HA possibly provides 
a bridge between these two CD44-positive populations. The 
demonstration that CD44 can act as a primary mediator of 
lymphocyte adhesion to smooth muscle ceils underscores the 
potential importance of substrates such as hyaluronate in leu- 
kocyte trafficking,  particularly in the context of inflamma- 
tion.  These results are consistent with our previous studies 
that indicated that CD44 expression is required for the gener- 
ation  of an  optimal  contact  allergic  response (46). 
There are a number of potentially important implications 
for lymphocyte-ASM cell interactions in the pathogenesis of 
asthma.  For example, smooth muscle cells are not classically 
considered antigen presenting cells. Several investigators have 
demonstrated,  however, that  VSM can express MHC class 
II antigens in response to IFN-3, stimulation  (47, 48). We 
have found that MHC class II expression by ASM cells also 
is induced by IFN-3' (our unpublished observation). It is there- 
fore possible that class II-expressing smooth muscle cells could 
serve an antigen presenting cells for preactivated T  cells in 
the asthmatic  airway. 
Another role of this interaction may be in regulating ASM 
cell growth.  We have demonstrated the ability of activated 
T lymphocytes to induce DNA synthesis in growth-arrested 
ASM. In addition, we found that maximal BrdU incorpora- 
tion and uptake of [3H]thymidine induced by T  cell adhe- 
sion to ASM coincided with the time necessary for serum- 
stimulated ASM cells to cycle through S phase as determined 
by propidium iodide staining (data not shown). If T cell in- 
duced BrdU incorporation  in ASM cells was due to DNA 
injury and repair, then we would not have expected such agree- 
ment in the time courses between these techniques. Whether 
this phenomenon  occurs via direct cell-cell contact and/or 
local production of mediators needs to be determined. How- 
ever, the ability of T  lymphocyte adhesion to induce ASM 
proliferation in vitro suggests that this interaction may con- 
tribute to the airway remodeling that occurs in these patients. 
In summary, this study has raised the possibility that the 
airway smooth muscle cell may be an important participant 
in the airway inflammatory response. ASM-lymphocyte in- 
teractions  may have effects on both  lymphocyte activation 
and function as well as on ASM cell growth and reactivity. 
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